Real World Evidence for Oritavancin Use in Gram-Positive Infections
Article full text
These articles are part of a supplement to Drugs – Real World Outcomes titled “Real World Evidence for Oritavancin Use in Gram-Positive Infections” wholly funded by Melinta Therapeutics. You can find the supplement here.
The above summary slides represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full texts online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.